Interactive Workshop on Lung Transplant Rejection

26 - 27 September 2023


Vienna University Hospital, Vienna, Austria

Vienna University Hospital, Vienna, Austria

More about the Centre

The Goal

The goal of the Lung Transplant Rejection Interactive Course is to provide the latest trends and
expert views on the treatment of Lung BOS with GvHD and foster discussion between peers.


Download Agenda PDF

Day 1 - 26 September 2023

Arrival of participants


20.00 – 20.15
Meeting at hotel lobby


Dinner with the faculty

Day 2 - 27 September 2023

09.00 – 09.10
Welcome and course goals introduction - Prof Peter Jaksch


09.10 – 09.55
Extracorporeal photopheresis in lung transplantation ‘how did we get there?’
a historic perspective from Zürich - Prof Christian Benden


09.55 – 10.10
Interactive discussion


10.10 – 10.30
Coffee break


10.30 – 11.15
Patient selection under times of changing definitions – the Hannover approach;
Patient selection and treatment algorithm - Dr Mark Greer


11.15 – 11.30
Interactive discussion


11.30 – 12.15
Vienna experiences and future directions - Prof Peter Jaksch


12.15 – 12.30
Interactive discussion


12.30 – 13.30


13.30 – 14.30
Patient cases discussion - All


14.30 – 15.00
ECP in lung transplantation – a patient perspective - Patient TBC


15.00 – 15.30
Final remarks and close - Prof Peter Jaksch


BOS: Bronchiolitis obliterans syndrome, GvHD: Graft versus Host Disease, ECP: Extracorporeal Photopheresis


For this course, participants are required to submit one patient case for discussion 15 days in
advance of the session


All speakers are subject to contract.
This is a commercial programme run by Therakos (UK) Ltd, part of Mallinckrodt Pharmaceuticals

This information is not intended for healthcare professionals based in the US and Canada.

Hosted by

Prof Peter Jaksch
Prof Peter Jaksch

Head of Lung Transplant Unit, Vienna Medical Hospital, Vienna, Austria

Brought to you by the Therakos Institute

This is a commercial programme run by Therakos (UK) Ltd, part of Mallinckrodt Pharmaceuticals